Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More

Alkem Labs acquires anti-nausea drug Marinol from AbbVie for $10 million

Marionol capsules are used to treat the loss of appetite (anorexia) in AIDS patients and to treat nausea and vomiting in patients receiving chemotherapy.

December 31, 2019 / 01:42 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Alkem Laboratories on December 31 announced that it is acquiring anti-nausea drug Marinol from US drug maker AbbVie for $10 million.

Marinol, generically called as Dronabinol, is a man-made or synthetic form of marijuana (cannabis).

Marionol capsules are used to treat the loss of appetite (anorexia) in AIDS patients and to treat nausea and vomiting in patients receiving chemotherapy.

"Assets as specified in the agreement in relation to the active pharmaceutical ingredient (API) Dronabinol which include domain names and trademarks related to "MARINOL", New Drug Application registration with USFDA for Marinol, logos, patents designs, know how, technical and manufacturing, inventory manufacturing equipment and such items," Alkem said in a statement to the exchanges.

Marinol is facing competition from generic equivalents of Akorn, Lannett, Insys and Svc Pharma and the prices of Dronabinol have dropped by over 60 percent.
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Dec 31, 2019 01:42 pm

stay updated

Get Daily News on your Browser
Sections